| Analysis | Metabolite Name | Measured Value | Units | Sample type | Gender |
|---|---|---|---|---|---|
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 41366 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 51275 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 53013 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 53439 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 63458 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 65285 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 72544 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 73096 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 79351 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 82096 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 85435 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 85453 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 86237 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 91511 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 91758 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 93490 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 98238 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 103618 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 104235 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 106799 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 109105 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 110601 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 111546 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 113130 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 113792 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 115948 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 117111 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 117206 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 120377 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 120949 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 122053 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 122572 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 126067 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 126856 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 127894 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 135612 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 135877 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 136483 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 136531 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 143962 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 149209 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 153821 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 157917 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 157971 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 160658 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 164593 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 172535 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 176475 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 176856 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 179109 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 179559 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 179625 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 182601 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 184774 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 185584 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 186355 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 192927 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 194691 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 194788 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 196527 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 198451 | Peak area normalized | chear plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 199082 | Peak area normalized | chear plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 203426 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 203498 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 204840 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 204852 | Peak area normalized | chear plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 206125 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 206257 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 206820 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 208820 | Peak area normalized | chear plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 209013 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 209586 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 209643 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 210361 | Peak area normalized | chear plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 211358 | Peak area normalized | chear plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 212106 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 213901 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 213911 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 214277 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 216572 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 216883 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 218632 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 220650 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 221905 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 223685 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 225383 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 230596 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 231825 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 231952 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 232727 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 235425 | Peak area normalized | chear plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 235617 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 235848 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 237555 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 238667 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 239675 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 241041 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 241071 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 241283 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 241790 | Peak area normalized | chear plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 246315 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 248603 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 251527 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 251745 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 252752 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 253759 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 256901 | Peak area normalized | red cross plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 260138 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 260174 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 260730 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 260923 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 261341 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 261469 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 262853 | Peak area normalized | red cross plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 263085 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 263908 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 264403 | Peak area normalized | red cross plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 265379 | Peak area normalized | chear plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 266639 | Peak area normalized | red cross plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 267053 | Peak area normalized | chear plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 267326 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 268139 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 269010 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 277327 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 278123 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 279331 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 279382 | Peak area normalized | master pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 280058 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 283686 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 284674 | Peak area normalized | master pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 284675 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 285452 | Peak area normalized | master pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 286404 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 288257 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 288839 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 290267 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 290278 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 290333 | Peak area normalized | master pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 290414 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 290482 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 290509 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 290935 | Peak area normalized | master pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 291109 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 291242 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 291366 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 291640 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 291708 | Peak area normalized | master pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 291859 | Peak area normalized | master pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 291918 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 292164 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 292166 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 292204 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 292292 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 292444 | Peak area normalized | master pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 292536 | Peak area normalized | master pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 292545 | Peak area normalized | red cross plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 292599 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 292780 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 292906 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 292937 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 293185 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 293494 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 293647 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 293912 | Peak area normalized | master pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 294022 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 294654 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 295100 | Peak area normalized | chear plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 295165 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 295229 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 295281 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 295293 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 295331 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 295412 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 295527 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 295740 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 295944 | Peak area normalized | red cross plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 296158 | Peak area normalized | master pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 296330 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 296351 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 296606 | Peak area normalized | master pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 297104 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 297305 | Peak area normalized | chear plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 297485 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 298088 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 298592 | Peak area normalized | batch pool | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 300624 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 301291 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 301951 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 304657 | Peak area normalized | red cross plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 306877 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 307496 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 309464 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 309688 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 309753 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 311069 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 316352 | Peak area normalized | red cross plasma | - |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 325466 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 325502 | Peak area normalized | Sample | male |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 325719 | Peak area normalized | Sample | female |
| Reversed Phase NEGATIVE (Named metabolites) | alpha-N-phenylacetylglutamine | 328809 | Peak area normalized | Sample | male |
Return to search page
